Global Information
회사소개 | 문의 | 비교리스트

강직성 척추염(AS) 치료제 시장 규모, 시장 점유율, 동향 분석(2020-2027년)

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By Region (North America, APAC, Europe, MEA), And Segment Forecasts, 2020 - 2027

리서치사 Grand View Research, Inc.
발행일 2020년 06월 상품 코드 943844
페이지 정보 영문 145 Pages
가격
US $ 5,950 ₩ 6,562,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 7,665,000 Printable PDF (5-User License)
US $ 8,950 ₩ 9,871,000 Printable PDF (Enterprise License)


강직성 척추염(AS) 치료제 시장 규모, 시장 점유율, 동향 분석(2020-2027년) Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By Region (North America, APAC, Europe, MEA), And Segment Forecasts, 2020 - 2027
발행일 : 2020년 06월 페이지 정보 : 영문 145 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 강직성 척추염(AS) 치료제 시장 규모는 2027년까지 79억 달러에 달하며, 예측기간 동안 연평균 복합 성장률(CAGR)은 8.3%를 나타낼 전망입니다. 강력한 제품 파이프라인의 존재가 시장 성장을 가속화 할 가능성이 있습니다. 예를 들어, UCB SA의 파이프라인 제품인 Bimekizumab는 Phase 2b의 긍정적인 결과로 인해 예측기간 동안 시장에 출시되는 의약품 후보가 될 가능성이 있습니다.

세계의 강직성 척추염(AS: Ankylosing Spondylitis) 치료제 시장에 대해 조사 분석했으며, 시장 개요, 부문별 시장 분석, 경쟁 상황, 주요 기업 등에 대해 체계적인 정보를 전해드립니다.

목차

제1장 조사 방법 및 범위

제2장 개요

제3장 강직성 척추염(AS) 치료제 시장의 변수, 동향, 범위

  • 보급률 및 성장 전망 매핑
  • 규제 프레임워크
  • 시장 역학
  • 강직성 척추염(AS) 치료제 시장 분석 툴

제4장 강직성 척추염(AS) 치료제 시장 : 경쟁 분석

  • 최근의 개발과 영향 분석 : 주요 시장 기업별
  • 기업/경쟁사 분류(주요 혁신 기업, 시장 리더, 신흥 기업)
  • 공개 기업
  • 비공개 기업

제5장 강직성 척추염(AS) 치료제 시장 : 의약품별 추정 및 동향 분석

  • 정의와 범위
  • 의약품별 시장 점유율 분석
  • 강직성 척추염(AS) 치료제 시장 : 유형별
  • 시장 규모 예측 및 동향 분석
    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • 기타

제6장 강직성 척추염(AS) 치료제 시장 : 지역별 추정 및 동향 분석

  • 강직성 척추염(AS) 치료제 시장 : 지역별 동향 분석
  • 강직성 척추염(AS) 치료제 시장 : 주요 기업
  • SWOT 분석 : 요인별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제7장 경쟁 상황

  • 전략적 프레임워크
  • 민간 기업 히트 맵 분석
  • Abbvie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • UCB Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Samsung Bioepis Co., Ltd.
  • Biothera Pharmaceuticals, Inc.
LSH 20.07.14

List of Tables

  • TABLE 1 List of abbreviations
  • TABLE 2 North America ankylosing spondylitis market estimates and forecasts, by country, 2016 - 2027 (USD Million)
  • TABLE 3 North America ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 4 US Ankylosing Spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 5 Canada ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 6 Europe ankylosing spondylitis market estimates and forecasts, by country, 2016 - 2027 (USD Million)
  • TABLE 7 Europe ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 8 U.K. ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 9 Germany ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 10 France ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 11 Spain ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 12 Italy ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 13 Asia Pacific ankylosing spondylitis market estimates and forecasts, by country, 2016 - 2027 (USD Million)
  • TABLE 14 Asia Pacific ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 15 Japan ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 16 China ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 17 India ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 18 Australia ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 19 South Korea ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 20 Latin America ankylosing spondylitis market estimates and forecasts, by country, 2016 - 2027 (USD Million)
  • TABLE 21 Latin America ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 22 Brazil ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 23 Mexico ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 24 Chile ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 25 Colombia ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 26 Argentina ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 27 Middle East & Africa ankylosing spondylitis market estimates and forecasts, by country, 2016 - 2027 (USD Million)
  • TABLE 28 Middle East & Africa ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 29 South Africa ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 30 Saudi Arabia ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)
  • TABLE 31 UAE ankylosing spondylitis market estimates and forecasts, by drug, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary, 2019
  • FIG. 4 Market trends & outlook
  • FIG. 5 Market segmentation & scope
  • FIG. 6 Market driver relevance analysis (Current & future impact)
  • FIG. 7 Market restrain relevance analysis (Current & future impact)
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 10 Porter's five forces analysis
  • FIG. 11 Ankylosing spondylitis market drug outlook key takeaways
  • FIG. 12 Ankylosing spondylitis market: Drug movement analysis
  • FIG. 13 Global ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 14 Cosentyx market, 2016 - 2027 (USD Million)
  • FIG. 15 Humira market, 2016 - 2027 (USD Million)
  • FIG. 16 Simponi market, 2016 - 2027 (USD Million)
  • FIG. 17 Remicade market, 2016 - 2027 (USD Million)
  • FIG. 18 Enbrel market, 2016 - 2027 (USD Million)
  • FIG. 19 Cimzia market, 2016 - 2027 (USD Million)
  • FIG. 20 Others market, 2016 - 2027 (USD Million)
  • FIG. 21 Regional market place: Key takeaways, 2019
  • FIG. 22 Regional outlook, 2019 & 2027
  • FIG. 23 North America ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 24 U.S. ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 25 Canada ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 26 Europe ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 27 U.K. ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 28 Germany ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 29 France ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 30 Spain ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 31 Italy ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 32 Asia Pacific ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 33 Japan ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 34 China ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 35 India ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 36 Australia ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 37 South Korea ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 38 Latin America ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 39 Brazil ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 40 Mexico ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 41 Chile ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 42 Colombia ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 43 Argentina ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 44 Middle East and Africa ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 45 South Africa ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 46 Saudi Arabia ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 47 UAE ankylosing spondylitis market, 2016 - 2027 (USD Million)
  • FIG. 48 Strategy framework
  • FIG. 49 Participant categorization

Ankylosing Spondylitis Market Growth & Trends

The global ankylosing spondylitis market size is expected to reach USD 7.9 billion by 2027 registering a CAGR of 8.3%, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province's public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Ankylosing Spondylitis Market Report Highlights

  • Humira was the largest revenue-generating drug in 2019 and accounted for over 25% of the market share due to the favorable pricing and lack of biosimilar competition in North America
  • Cosentyx is estimated to be the fastest-growing segment due to its excellent clinical profile. In addition, the product is patent protected for ankylosing spondylitis till 2033 in U.S. till and 2030 in Europe
  • North America led the market in 2019 due to the presence of key biopharmaceutical & pharmaceutical companies and increased funding and research initiatives
  • Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
  • For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Table of Contents

Chapter 1. Methodology and Scope

      • 1.1.Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & Third party perspectives
    • 1.3.4. Primary research
  • 1.4. Information Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ankylosing Spondylitis Market Variables, Trends & Scope

  • 3.1. Penetration & Growth Prospect Mapping
  • 3.2. Regulatory Framework
    • 3.2.1. Reimbursement framework
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing penetration of key players in the AS market
      • 3.3.1.2. Presence of strong product pipeline
      • 3.3.1.3. Favorable reimbursement policies
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Patent expiry of blockbuster drugs
  • 3.4. Ankylosing Spondylitis Market Analysis Tools
    • 3.4.1. Industry analysis - Porter's
      • 3.4.1.1. Supplier power (Moderate due to requirement of high - quality raw materials)
      • 3.4.1.2. Buyer power (High due to limited number of established providers)
      • 3.4.1.3. Substitution threat (Low due to clinical development of new compounds)
      • 3.4.1.4. New entrants' threat (High as the market is underserved)
      • 3.4.1.5. Competitive rivalry (High due to presence of key players)
    • 3.4.2. PESTEL analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Environmental landscape
      • 3.4.2.3. Social landscape
      • 3.4.2.4. Technology landscape
      • 3.4.2.5. Legal landscape
    • 3.4.3. Major deals & strategic alliances analysis
      • 3.4.3.1. Joint ventures
      • 3.4.3.2. Mergers & acquisitions

Chapter 4. Ankylosing Spondylitis Market - Competitive Analysis

  • 4.1. Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 4.3. Public Companies
    • 4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 4.3.2. Company market share
    • 4.3.3. Synergy analysis: Major deals & strategic alliances
  • 4.4. Private Companies
    • 4.4.1. List of key emerging companies
    • 4.4.2. Regional network map
    • 4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Ankylosing Spondylitis Market: Drug Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Drug Market Share Analysis, 2019 & 2027
  • 5.3. Ankylosing Spondylitis Market, by Type, 2016 to 2027
  • 5.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 5.4.1. Cosentyx
      • 5.4.1.1 Cosentyx market, 2016 - 2027 (USD Million)
    • 5.4.2 Humira
      • 5.4.2.1 Humira market, 2016 - 2027 (USD Million)
    • 5.4.3 Simponi
      • 5.4.2.1 Humira market, 2016 - 2027 (USD Million)
    • 5.4.4 Remicade
      • 5.4.4.1 Remicade market, 2016 - 2027 (USD Million)
    • 5.4.5 Enbrel
      • 5.4.5.1 Enbrel market, 2016 - 2027 (USD Million)
    • 5.4.6 Cimzia
      • 5.4.6.1 Cimzia market, 2016 - 2027 (USD Million)
    • 5.5.6 Others
      • 5.5.6.1 Others market, 2016 - 2027 (USD Million)

Chapter 6 Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis, by Drug

  • 6.1 Ankylosing Spondylitis Market: Regional Movement Analysis, 2019 & 2027
  • 6.2 Ankylosing Spondylitis Market: Leading Players, 2019:
    • 6.2.1. North America
    • 6.2.2. Europe
    • 6.2.3. Asia Pacific
    • 6.2.4. Latin America
    • 6.2.4. Middle East & Africa
  • 6.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 6.3.1. North America
    • 6.3.2. Europe
    • 6.3.3. Asia Pacific
    • 6.3.4. Latin America
    • 6.3.5. Middle East & Africa
  • 6.4 North America
    • 6.4.1 North America market, 2016 - 2027 (USD Million)
    • 6.4.2 U.S.
      • 6.4.2.1 U.S. market, 2016 - 2027 (USD Million)
    • 6.4.3 Canada
      • 6.4.3.1 Canada market, 2016 - 2027 (USD Million)
  • 6.5. Europe
    • 6.5.1 Europe market, 2016 - 2027 (USD Million)
    • 6.5.2 U.K.
      • 6.5.2.1 U.K. market, 2016 - 2027 (USD Million)
    • 6.5.3 Germany
      • 6.5.3.1 Germany market, 2016 - 2027 (USD Million)
    • 6.5.4 France
      • 6.5.4.1 France market, 2016 - 2027 (USD Million)
    • 6.5.5 Italy
      • 6.5.5.1 Italy market, 2016 - 2027 (USD Million)
    • 6.5.6 Spain
      • 6.5.6.1 Spain market, 2016 - 2027 (USD Million)
  • 6.6 Asia Pacific
    • 6.6.1 Asia Pacific market, 2016 - 2027 (USD Million)
    • 6.6.2 Japan
      • 6.6.2.1 Japan market, 2016 - 2027 (USD Million)
    • 6.6.3 China
      • 6.6.3.1 China market, 2016 - 2027 (USD Million)
    • 6.6.4 India
      • 6.6.4.1 India market, 2016 - 2027 (USD Million)
    • 6.6.5 Australia
      • 6.6.5.1 Australia market, 2016 - 2027 (USD Million)
    • 6.6.6 South Korea
      • 6.6.6.1 South Korea market, 2016 - 2027 (USD Million)
  • 6.7 Latin America
    • 6.7.1 Latin America market, 2016 - 2027 (USD Million)
    • 6.7.2 Brazil
      • 6.7.2.1 Brazil market, 2016 - 2027 (USD Million)
    • 6.7.3 Mexico
      • 6.7.3.1 Mexico market, 2016 - 2027 (USD Million)
    • 6.7.4 Chile
      • 6.7.4.1 Chile market, 2016 - 2027 (USD Million)
    • 6.7.5 Colombia
      • 6.7.5.1 Colombia market, 2016 - 2027 (USD Million)
    • 6.7.6 Argentina
      • 6.7.6.1 Argentina market, 2016 - 2027 (USD Million)
  • 6.8 Middle East & Africa
    • 6.8.1 Middle East & Africa market, 2016 - 2027 (USD Million)
    • 6.8.2 South Africa
      • 6.8.2.1 South Africa market, 2016 - 2027 (USD Million)
    • 6.8.3 Saudi Arabia
      • 6.8.3.1 Saudi Arabia market, 2016 - 2027 (USD Million)
    • 6.8.4 UAE
      • 6.8.4.1 UAE market, 2016 - 2027 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Heat Map Analysis of Private Companies
    • 7.2.1 Company size
    • 7.2.2 Distribution network
    • 7.2.3 Product portfolio
    • 7.2.4 Segment coverage
    • 7.2.5 Geographic presence
    • 7.2.6 Collaborations
    • 7.2.7 Conclusion
  • 7.3 Abbvie Inc.
    • 7.3.1 Company overview
    • 7.3.2 Financial performance
    • 7.3.3 Product benchmarking
    • 7.3.4 Strategic initiatives
  • 7.4 Amgen Inc.
    • 7.4.1 Company overview
    • 7.4.2 Financial performance
    • 7.4.3 Product benchmarking
    • 7.4.4 Strategic initiatives
  • 7.5 Pfizer Inc.
    • 7.5.1 Company overview
    • 7.5.2 Financial performance
    • 7.5.3 Product benchmarking
    • 7.5.4 Strategic initiatives
  • 7.6 Johnson & Johnson Services, Inc.
    • 7.6.1 Company overview
    • 7.6.2 Financial performance
    • 7.6.3 Product benchmarking
    • 7.6.4 Strategic initiatives
  • 7.7 Merck & Co., Inc.
    • 7.7.1 Company overview
    • 7.7.2 Financial performance
    • 7.7.3 Product benchmarking
    • 7.7.4 Strategic initiatives
  • 7.8 UCB Inc.
    • 7.8.1 Company overview
    • 7.8.2 Financial performance
    • 7.8.3 Product benchmarking
    • 7.8.4 Strategic initiatives
  • 7.9 Eli Lilly and Company
    • 7.9.1 Company overview
    • 7.9.2 Financial performance
    • 7.9.3 Product benchmarking
    • 7.9.4 Strategic initiatives
  • 7.10 Novartis AG
    • 7.10.1 Company overview
    • 7.10.2 Financial performance
    • 7.10.3 Product benchmarking
    • 7.10.4 Strategic initiatives
  • 7.11 Samsung Bioepis Co., Ltd.
    • 7.11.1 Company overview
    • 7.11.2 Financial performance
    • 7.11.3 Product benchmarking
    • 7.11.4 Strategic initiatives
  • 7.12 Biothera Pharmaceuticals, Inc.
    • 7.12.1 Company overview
    • 7.12.2 Financial performance
    • 7.12.3 Product benchmarking
    • 7.12.4 Strategic initiatives
Back to Top
전화 문의
F A Q